Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05756920 · ClinicalTrials.gov registry record · Phase 1
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
A Phase 1 study of Healthy, sponsored by ABL Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT05756920: Completed Phase 1 study of Healthy, sponsored by ABL Bio.
NCT05756920 is a Phase 1 study of Healthy that has completed, run by ABL Bio. The registered enrollment target is 91 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05756920, a Phase 1 study of Healthy, has completed, sponsored by ABL Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, FIH, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, PK and PD after SAD and MAD in healthy adult participants.
Primary Outcome
Number of participants with AEs
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABL301
Study Locations (1)
Texas
- PPD Development, LP - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-12-31 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
What the finished NCT05756920 record still lists
NCT05756920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05756920 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05756920 about?
NCT05756920 is a clinical study titled "This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants". This is a Phase 1, FIH, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, PK and PD after SAD and MAD in healthy adult participants.
What is the current status of trial NCT05756920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2022-12-31. Estimated completion is 2025-04-30.
What conditions does trial NCT05756920 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05756920?
The interventions under investigation include: Placebo (DRUG), ABL301 (DRUG).
Who is sponsoring clinical trial NCT05756920?
This trial is sponsored by ABL Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05756920 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05756920's enrollment target sits among peer trials
91 249th of 1090 higher than 840 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
- NCT05847192 · 91 participants
Tau Networks in Psychotic Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI